Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates

Kirk M. Brown, Martin A. Maier, Vasant Jadhav, et al, Nature Biotechnology (2022).

https://doi.org/10.1038/s41587-022-01334-x

Vasant Jadhav, PhD
Alnylam Pharmaceuticals

Biography:
Vasant Jadhav is a Senior Vice President of Research at Alnylam Pharmaceuticals, where he leads the RNAi Platform Technology group responsible for siRNA designs, new applications and delivery solutions including conjugate and LNP approaches that have led to 4 approved drugs and deep pipeline across multiple tissue targets. Prior to Alnylam, Vasant was at Sirna/Merck for 12 years and worked on optimizing siRNA chemical modifications and leading the efforts on conjugate delivery approach. He obtained his PhD in Biotechnology from the University of Pune in 1998 and post-doctoral fellowship at University of Colorado, Boulder working on ribozymes. Dr. Jadhav has authored >30 peer-reviewed publication in the field of nucleic acids therapeutics.